ECEESPE2025 ePoster Presentations Diabetes and Insulin (245 abstracts)
1Farhat Hached University Hospital, Endocrinology - Diabetology Departement, Sousse, Tunisia; 2Farhat Hached University Hospital, Endocrinology - Diabetology Departement, Sousse, Tunisia; 3Farhat Hached University Hospital, Endocrinology - Diabetology Departement, Sousse, Tunisia; 4Farhat Hached University Hospital, Endocrinology - Diabetology Departement, Sousse, Tunisia
JOINT3001
Introduction: Non-alcoholic hepatic steatosis has become the leading cause of chronic liver disease in the world. Our aim was to assess the prevalence of hepatic fibrosis by Fibroscan in unbalanced type 2 diabetic (T2D) patients with no known liver disease.
Patients and methods: Prospective cross-sectional study including 30 T2D followed at the endocrinology department CHU Farhat-Hached. A Fibroscan and a hepatic work-up were performed. Patients with known chronic liver disease were excluded.
Results: The mean age was 52.9±11.7 years, 53% of patients were male. The mean duration of diabetes was 9±7.6 years old. Only 23.1% had a normal weight, compared with 46.1% with a BMI >30kg/m2. Android obesity was present in 92.2%, with an average waist circumference of 103 cm. Diabetes was unbalanced in 71.4% of patients, with a mean HBA1c of 9.22±2.22%. Cytolysis was found in 9.5% and no patient presented with cholestasis. Median elasticity was 6.48±3.63 kPa. Fibrosis was confirmed in 41.4% and 13.8% had advanced fibrosis (F≥3). Among the cohort, 20% of obese patients had hepatic fibrosis, including 10% with severe fibrosis. Unbalanced diabetes was noted in 29.6% of cases of Fibrosis (P<0,001).
Conclusion: Unbalanced type 2 diabetes and obesity are among the factors that accelerate progression to liver fibrosis in non-alcoholic steatosis.